Use of foreign comparator data to demonstrate biosimilarity should only be allowed if the foreign product is made by the same company and/or in the same facility as the U.S.-licensed reference product, the three major pharmaceutical and biotechnology trade groups say in comments on FDA’s biosimilar draft guidances.
The source of foreign reference products seems to be a rare area of agreement among the innovator industry groups –...